Asian Myeloproliferative Neoplasm (MPN) Registry

Status Recruiting

Clinical Trial Summary

This is a multinational, multicenter, prospective and retrospective, observational, cohort study of patients with myeloproliferative neoplasm.

Clinical Trial Description

This is a multinational, multicenter, prospective and retrospective, observational, cohort registry of patients with MPN. The registry mainly involves study centres in Asia including but not limited to Hong Kong, Singapore, Malaysia, Taiwan, Korea and Thailand. Clinicopathologic characteristics, cytogenetic characteristics, mutational characteristics, treatment characteristics, outcomes and survivals of Asian patients MPN diagnosed between 2010-2025 will be collected to establish clinical registry. Data on the clinicopathologic characteristics, cytogenetics, mutational profile, prognostic scoring treatment characteristics, responses to treatment, outcome and survivals will be collected through routine clinic visits and/or reviewing medical records. Data will be collected at diagnosis, and approximately every 6 months thereafter (for prospective data) and at progression until death/study termination. ;

Study Design

Related Conditions & MeSH terms

Essential Thrombocythemia
Myeloproliferative Disorders
Myeloproliferative Neoplasm
Neoplasms
Polycythemia
Polycythemia Vera
Post-essential Thrombocythemia Myelofibrosis
Post-polycythemia Vera Myelofibrosis
Primary Myelofibrosis
Primary Myelofibrosis, Fibrotic Stage
Primary Myelofibrosis, Prefibrotic Stage
Thrombocythemia, Essential
Thrombocytosis

Clinical Trial Details

NCT number	NCT05882773
Study type	Observational [Patient Registry]
Source	The University of Hong Kong
Contact	Harinder Gill, MD
Phone	+852 22554542
Email	gillhsh@hku.hk
Status	Recruiting
Phase
Start date	May 2023
Completion date	December 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01178281` - Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence	Phase 3
Not yet recruiting	`NCT06327100` - Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)	Phase 2
Active, not recruiting	`NCT00095784` - Decitabine in Treating Patients With Myelofibrosis	Phase 2
Recruiting	`NCT02897297` - Myeloproliferative Neoplastic Diseases Observatory From Brest
Terminated	`NCT02091752` - A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)	Phase 2
Completed	`NCT01445769` - Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis	Phase 2
Completed	`NCT01233921` - Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer	N/A
Unknown status	`NCT01298934` - LBH589 (Panobinostat) for the Treatment of Myelofibrosis	Phase 1/Phase 2
Terminated	`NCT00387426` - Sunitinib in Treating Patients With Idiopathic Myelofibrosis	Phase 2
Completed	`NCT05044026` - A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis
Active, not recruiting	`NCT03952039` - An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib	Phase 3
Active, not recruiting	`NCT02530619` - Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia	N/A
Completed	`NCT01588015` - Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant	Phase 1
Completed	`NCT01731951` - Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis	Phase 2
Completed	`NCT01371617` - A Phase 2 Study With IPI-926 in Patients With Myelofibrosis	Phase 2
Active, not recruiting	`NCT02251821` - JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis	Phase 2
Active, not recruiting	`NCT04446650` - A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)	Phase 1/Phase 2
Completed	`NCT01981850` - A Phase 2 Study of RO7490677 In Participants With Myelofibrosis	Phase 2
Withdrawn	`NCT04283526` - Study of Select Combinations in Adults With Myelofibrosis	Phase 1
Withdrawn	`NCT02584777` - A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis	Phase 2